• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by MetaVia Inc.

    6/8/26 4:30:42 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    S-8 1 tm2615356d1_s8.htm FORM S-8

     

    Registration No. 333-      

    As filed with the Securities and Exchange Commission on June 8, 2026

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    MetaVia INC.
    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2389984
    (State or other jurisdiction of incorporation or organization)   (IRS Employer Identification Number)
       

    545 Concord Avenue, Suite 210

    Cambridge, MA

      02138
    (Address of Principal Executive Offices)   (Zip code)

     

    MetaVia Inc. Amended and Restated 2022 Equity Incentive Plan

    (Full title of the plan)

     

    Hyung Heon Kim
    President, Chief Executive Officer and Director
    MetaVia Inc.

    545 Concord Avenue, Suite 210

    Cambridge, MA 02138
    (Name and address of agent for service)

     

    857-702-9600

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:
    Phillip D. Torrence, Esq.
    Joshua W. Damm, Esq.
    Honigman LLP
    650 Trade Centre Way, Suite 200
    Kalamazoo, Michigan 49002
    Tel: (269) 337-7700

    Fax: (269) 337-7703

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     Large accelerated filer ¨ Accelerated filer   ¨
           
    Non-accelerated filer x Smaller reporting company   x
           
        Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed by MetaVia Inc. (the “Registrant,” “we,” “us” or “our”) for the purpose of registering an additional 200,000 shares of common stock, par value $0.001 per share (the “Common Stock”), issuable under the MetaVia Inc. Amended and Restated 2022 Equity Incentive Plan, as amended (the “2022 Incentive Plan”). These additional shares of Common Stock were reserved for issuance in connection with the amendment to the 2022 Incentive Plan, which was approved by stockholders on June 8, 2026 at the Company’s 2026 Annual Meeting of Stockholders. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous registration statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on April 17, 2023 (Registration No. 333-271292), March 27, 2025 (Registration No. 333-286184) and April 3, 2026 (Registration No. 333-294877) to the extent not superseded hereby.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference (other than information in such filings that was “furnished” under the applicable Commission rules rather than “filed”):

     

    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 26, 2026 (the “Annual Report”);

     

    (b)all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

     

    (c)the description of the Registrant’s Common Stock which is contained in the Registration Statement on Form 8-A filed with the Commission on June 20, 2016 (File No. 001-37809) under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information, shall not be deemed to be incorporated by reference in this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    The following exhibits are filed as part of this Registration Statement.

     

    INDEX TO EXHIBITS

     

    Exhibit      

    Incorporated by Reference

    Number   Description   Form   File No.   Exhibit   Filing Date
    3.1   Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   8/10/2016
    3.2   Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   12/31/2019
    3.3   Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.2   12/31/2019
    3.4   Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   9/12/2022
    3.5   Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   12/19/2023
    3.6   Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   11/18/2024
    3.7   Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant   8-K   001-37809   3.1   12/02/2025
    3.8   Fourth Amended and Restated Bylaws of the Registrant   8-K   001-37809   3.2   11/18/2024
    5.1*   Opinion of Honigman LLP                
    23.1*   Consent of BDO USA, P.C., Independent Registered Public Accounting Firm                
    23.2*   Consent of Honigman LLP (included in Exhibit 5.1)                
    24.1*   Power of Attorney of certain directors and officers of the Registrant (contained on signature page)                
    99.1   Amended and Restated 2022 Equity Incentive Plan of the Registrant, as amended November 29, 2024, and forms of award agreements   10-K   001-37809   10.7   3/20/2025
    99.2   First Amendment to the Amended and Restated 2022 Equity Incentive Plan of the Registrant   8-K   001-37809   10.1   6/8/2026
    107*   Filing Fee Table                

     

     

    *            Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on June 8, 2026.

     

      METAVIA INC.
         
      By: /s/ Hyung Heon Kim
        Name: Hyung Heon Kim
        Title: President, Chief Executive Officer and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hyung Heon Kim and Andrew I. Koven, and each of them, as his true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments and to file the same, with any exhibits thereto and other documents in connection therewith, with the Commission, or any state securities department or any other federal or state agency or governmental authority granting unto such attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

     

    Signature   Title   Date
         
    /s/ Hyung Heon Kim   President, Chief Executive Officer (Principal Executive   June 8, 2026
    Hyung Heon Kim   Officer) and Director    
             
    /s/ Marshall H. Woodworth   Chief Financial Officer (Principal Financial Officer and   June 8, 2026
    Marshall H. Woodworth   Principal Accounting Officer)    
         
    /s/ Andrew I. Koven   Chairman of the Board of Directors   June 8, 2026
    Andrew I. Koven        
         
    /s/ Mark A. Glickman   Director   June 8, 2026
    Mark A. Glickman        
         
    /s/ Jason L. Groves   Director   June 8, 2026
    Jason L. Groves        
             
    /s/ Michael Salsbury   Director   June 8, 2026
     Michael Salsbury        
             
    /s/ D. Gordon Strickland   Director   June 8, 2026
    D. Gordon Strickland        
             
    /s/ James P. Tursi, M.D.   Director   June 8, 2026
    James P. Tursi, M.D.        

     

     

     

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    SEC Filings

    View All

    SEC Form S-8 filed by MetaVia Inc.

    S-8 - MetaVia Inc. (0001638287) (Filer)

    6/8/26 4:30:42 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    6/8/26 4:00:57 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    6/8/26 9:01:47 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

    DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauVanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH ModelVanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D ModelCAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Associati

    6/8/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

    CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questi

    6/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

    48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauExploratory FibroScan Assessments Demonstrated Early Liver-Related ImprovementsOngoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose LevelsCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Ass

    5/27/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:59 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:28 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:32:08 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care